Ardent Health Partners, INC 8-K filings

Ardent Health, Inc. disclosed details of a separation agreement with former CEO Martin J. Bonick, outlining severance benefits and restrictive covenants.

Ardent Health announced Dave Caspers as its new CEO, succeeding Martin J. Bonick, and reaffirmed its full-year 2026 Adjusted EBITDA guidance.

Ardent Health, Inc. held its Annual Meeting of Stockholders on May 20, 2026, where directors were elected, executive compensation was approved advisory, and auditors were ratified.

Ardent Health announced first quarter 2026 financial results, showing a 7.0% increase in total revenue and a 26.3% rise in Adjusted EBITDA, while reaffirming its full-year guidance.

Ardent Health, Inc. announced the departure of Ethan Chernin as President, Hospital Services, effective March 24, 2026, with severance benefits.

Ardent Health, Inc. announced its fourth quarter and full-year 2025 financial results, showing solid 2025 growth but issuing prudent 2026 guidance due to industry headwinds.

Ardent Health's Board of Directors has authorized a new share repurchase program of up to $50 million, signaling confidence in its financial strength and future growth.

Ardent Health reported a $23 million net loss in Q3 2025 and revised its full-year Adjusted EBITDA guidance downward due to higher professional fees and increased payor denials.

Ardent Health successfully amended and extended its $777.5 million Term Loan Facility, reducing the interest rate by 50 basis points and extending maturity to September 2032, which is expected to save $3.9 million annually.

Ardent Health, Inc. announced robust second quarter 2025 financial results, with significant revenue and Adjusted EBITDA growth, while reaffirming its full-year 2025 guidance.

Ardent Health, Inc. announced the immediate departure of David Schultz, President of Hospital Operations, effective June 16, 2025, with his separation treated as a qualifying termination under the company's severance plan.

Ardent Health Partners, Inc. announced its legal name change to Ardent Health, Inc., effective June 3, 2025, and reported the outcomes of its annual stockholders' meeting, including the election of 11 directors and advisory approval of executive compensation.

Ardent Health Partners, Inc. announced its first quarter 2025 financial results, reporting revenue growth and reaffirming its full-year 2025 guidance.

Ardent Health Partners expands its Board of Directors to 11 members with the appointment of Robert A. DeMichiei, effective April 2, 2025.

Ardent Health Partners appoints David Caspers as COO to oversee operations across its 30 hospitals and 280 sites of care, while also announcing promotions for three senior leaders.

Ardent Health Partners announces impressive fourth-quarter and full-year 2024 results, driven by revenue growth and a significant increase in Adjusted EBITDA, while also issuing strong financial guidance for 2025.

Ardent Health Partners has amended employment agreements for its CEO and CFO and provided a preliminary financial outlook for 2025, including revenue and adjusted EBITDA growth.

Ardent Health Partners announced a 5.2% year-over-year revenue increase to $1.45 billion and a 15.3% increase in adjusted EBITDA to $98 million for the third quarter of 2024, leading to raised full-year guidance.

Ardent Health Partners reported a 7.5% increase in revenue and a 20% increase in adjusted EBITDA for the second quarter of 2024, driven by strategic initiatives and operational improvements.